Regulators still evaluate the complete evidence package, manufacturing controls, labeling, and the balance of benefits and risks
Factors that may exacerbate the symptoms include: stress periods eating certain foods, such as fish, beans, or eggs sweating In many cases, the disorder is genetic and causes no other symptoms
The CMS BALANCE model offers states a path to expand coverage: states can opt into the model between May 2026 and January 2027, and CMS will negotiate lower drug pricing with manufacturers on behalf of participating states
The efficacy of the specific enzyme blend used in AllerGzyme is supported by robust clinical data
Our team will discuss your medical history thoroughly to ensure the safest treatment plan
They are not approved for human use by the FDA outside of clinical trials